Spain’s Grifols accused of manipulating finances by short seller Gotham City, stock plummets news2024-01-09T21:43:13+00:00January 9th, 2024|Endpoints News|
Lupus drug market growing as physicians adopt newer options — and look for more, research findsnews2024-01-09T21:06:49+00:00January 9th, 2024|Endpoints News|
FDA chief taps Elizabeth Jungman as new chief of staff, starting later this monthnews2024-01-09T20:35:24+00:00January 9th, 2024|Endpoints News|
As Congress debates orphan reforms, new analysis finds 65% of orphan drugs approved for a single rare diseasenews2024-01-09T19:56:33+00:00January 9th, 2024|Endpoints News|
MiMedx receives FDA warning letter over Axiofill manufacturing concernsnews2024-01-09T19:29:10+00:00January 9th, 2024|Endpoints News|
#JPM24: Illumina reports stronger-than-expected growth, indicates Grail divestiture still in early stagesnews2024-01-09T18:50:17+00:00January 9th, 2024|Endpoints News|
#JPM24: Merck is eyeing new immunology deals, chief medical officer saysnews2024-01-09T18:05:38+00:00January 9th, 2024|Endpoints News|
Novartis CEO plays down Cytokinetics buyout rumors in CNBC interviewnews2024-01-09T17:55:38+00:00January 9th, 2024|Endpoints News|
TG licenses Precision’s cell therapy; Innovent’s PhIII weight loss win; Atea’s positive hep C datanews2024-01-09T17:30:09+00:00January 9th, 2024|Endpoints News|
Lantheus hands Perspective Therapeutics $28M upfront to expand its radiopharma optionsnews2024-01-09T17:28:04+00:00January 9th, 2024|Endpoints News|
